Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Riverwater Micro Opportunities Strategy Nathan Fredrick, CFA | “AnaptysBio ($ANAB) was recently reconstituted into a biopharmaceutical royalty aggregator following the spin-off of its clinical pipeline into First Tracks Biotherapeutics. The manager initiated a bullish position, identifying an overlooked asymmetric royalty cash-flow structure that trades at an extreme discount to fair present value. The investment thesis is anchored in a high-margin, capital-light 8% to 25% tiered royalty stream on global sales of GSK's PD-1 checkpoint inhibitor Jemperli. With Jemperli revenues expanding 34% year-over-year and GSK targeting peak sales exceeding $2.7 billion, AnaptysBio's baseline cash flows could generate over $390 million in annual high-margin royalties by 2029 once historical royalty monetization debt clears in 2027. This provides high free cash flow conversion without ongoing clinical trials or R&D capital commitments. Near-term catalysts include an FDA regulatory decision on Jemperli for rectal cancer in February 2027, an approval verdict on partner drug Quimilza in December 2026, and legal adjudication in late 2026 or early 2027 concerning collaboration disputes with GSK. Key risks center on litigation setbacks, adverse regulatory rulings, or commercial shortfall of Jemperli against rival oncology therapies.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
“AnaptysBio is a drug royalty company. In 2014, Tesaro licensed a portfolio of pre-clinical antibodies from AnaptysBio. Tesaro, then a small company with $180M in cash, paid AnaptysBio $17M under an agreement designed for two small companies. Five years later, in 2019, GlaxoSmithKline acquired Tesaro. In 2021, AnaptysBio's cancer drug Jemperli was approved. Five years after that, GSK spent $10.6B to acquire Nuvalent and their cancer portfolio. This year, Jemperli will generate more than $1B of revenue for GSK. AnaptysBio is suing GSK for allegedly violating provisions governing notification, exclusivity, and commercial optimization through a trial involving another cancer drug. This is the second time AnaptysBio has sued GSK. The first lawsuit settled for a $60M cash payment and a near doubling of the royalty rates. A settlement or sale appears likely for three reasons: 1) Delaware courts tend to push parties toward settlements. 2) If Anaptys prevails on its material-breach and reversion claims, GSK could ultimately lose the rights to Jemperli, a $1B-plus drug that is still growing. 3) AnaptysBio's directors and executive officers beneficially own approximately 31.5% of the company, creating substantial alignment with shareholders. At the trial, it was disclosed that GSK had tried to buy AnaptysBio three times in the past year. Before the ruling, I believe the most likely outcome is that GSK acquires AnaptysBio for a price more than 50% above our purchase price.” | NEUTRAL | Q2 2026 Aug 14, 2026 | View Pitch | |
Laughing Water Capital Matthew Sweeney | “AnaptysBio is a special situation that I expect will resolve itself very quickly. In brief, following the recently completed taxable spinoff of their developmental drug assets, Anaptys is now an asset light royalty company primarily collecting tolls on the sales of Jemperli, a fast-growing cancer drug that is being commercialized in partnership with GSK. If this were where the story ended, I believe we would have purchased our shares at a reasonable discount to the present value of the future royalty payments. However, AnaptysBio has the potential for lotto ticket upside in the near-immediate future as they have accused GSK of violating the terms of their commercial agreement, and a trial has been set for July 14-17. My read of the situation suggests that GSK is in a very weak position with a lot to lose because if AnaptysBio is successful at trial, they could recover the entirety of Jemperli. In this low probability scenario, ANAB shares could be worth nearly $300, vs our average purchase price of below $60. A much higher probability scenario is that GSK chooses to settle before trial, or perhaps even buy Anaptysbio outright. I expect that these scenarios could result in 50-80+% upside for our investment.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.